Authors





Alexander Guminski, MD, PhD

Latest:

Dr. Guminski on 16-Month Follow-Up With Cemiplimab in mCSCC

Alexander Guminski, MD, PhD, medical oncologist, Royal North Shore Hospital, University of Sydney, discusses the 16-month follow-up results of a phase II trial evaluating cemiplimab (Libtayo) in patients with metastatic cutaneous squamous cell carcinoma.



Alexander J. Stratigos, MD

Latest:

Dr. Stratigos the Rationale to Evaluate Cemiplimab in Locally Advanced BCC

Alexander J. Stratigos, MD, discusses the rationale to evaluate cemiplimab-rwlc in locally advanced basal cell carcinoma.


Alexander Kutikov, MD

Latest:

Fox Chase Investigates Screening Methods to Avoid Unnecessary Radical Cystectomy

Currently, there is no reliable way to identify who can safely avoid radical cystectomy following MIBC treatment. For this reason, Fox Chase Cancer Center researchers are trying to find the as-yet-elusive 30% by asking 3 important questions.


Alexander Kutikov, MD, FACS

Latest:

Dr. Kutikov on Tumor Pathology in Renal Cell Carcinoma

Alexander Kutikov, MD, FACS, attending surgeon, urologic oncology, associate professor, urologic oncology, Fox Chase Cancer Center, discusses the understanding of tumor pathology in renal cell carcinoma.


Alexander Leandros Lazarides, MD

Latest:

Dr. Lazarides on Research Regarding Margin Assessment in Sarcoma

Alexander Leandros Lazarides, MD, discusses research regarding margin assessment in patients with sarcoma.


Alexander M. Lesokhin, MD

Latest:

Dr. Lesokhin on the Utility of Elranatamab in Relapsed/Refractory Multiple Myeloma

Alexander M. Lesokhin, MD, discusses the utility of elranatamab in the ongoing phase 2 MagnetisimMM-3 trial in relapsed/refractory multiple myeloma.


Alexander M. M. Eggermont, MD, PhD

Latest:

Dr. Eggermont on the Rationale for Evaluating Adjuvant Pembrolizumab in Advanced Melanoma

Alexander M. M. Eggermont, MD, PhD, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, ​evaluating adjuvant pembrolizumab versus placebo, in advanced melanoma.


Alexander N. Shoushtari, MD

Latest:

Dr. Shoushtari on the Rationale for the CheckMate-067 Trial in Advanced Melanoma

Alexander N. Shoushtari, discusses the rationale for the ​phase 3 CheckMate-067 trial in advanced melanoma.




Alexander R. Menter, MD

Latest:

Dr. Menter on Neoadjuvant Immunotherapy in Early-Stage NSCLC

Alexander R. Menter, MD, oncologist, Kaiser Permanente, discusses the use of neoadjuvant immunotherapy in patients with early-stage non–small cell lung cancer (NSCLC).


Alexander Ring, MD

Latest:

Dr. Ring on Molecular Profiling of CTCs in Advanced Breast Cancer

Alexander Ring, MD, graduate student, University of Southern California, discusses a study investigating the molecular profiling of circulating tumor cells (CTCs) as a surrogate for distant metastasis in patients with stage IV breast cancer.


Alexander Spira, MD, PhD, FACP

Latest:

Dr Spira on the Evaluation of Fianlimab Plus Cemiplimab in Advanced Melanoma

Alexander I. Spira, MD, PhD, FACP, discusses the evaluation of the LAG-3 inhibitor fianlimab plus cemiplimabin patients with advanced melanoma who were PD-L1 inhibitor–naïve, as seen in the findings from a phase 1 study.


Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

Latest:

Amivantamab + Lazertinib Versus Osimertinib as 1L Treatment in EGFR-Mutated Advanced NSCLC: Primary Results From MARIPOSA

Expert oncologist Alex Spira, MD, PhD, FACP, reviews primary results from the MARIPOSA study in advanced NSCLC following the ESMO 2023 annual meeting.


Alexandra Drakaki, MD

Latest:

Dr. Drakaki on the Design of the MORPHEUS-mUC Trial in Urothelial Carcinoma

Alexandra Drakaki, MD, discusses the design of the MORPHEUS-mUC trial in advanced/metastatic urothelial carcinoma.


Alexandra Taylor, MD

Latest:

Dr. Taylor on the Future of Treatments for Endometrial Cancer

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the future of treatments for patients with endometrial cancer.


Alexandra Thomas, MD

Latest:

Targeting Cell Cycle Progression: CDK4/6 Inhibition in Breast Cancer

Cyclin-dependent kinase (CDK) 4/6 inhibitors are novel agents that have shown promising results in the treatment of breast cancer.


Alexandria Phan, MD

Latest:

Dr. Phan Discusses Challenges With Treating pNETs

Alexandria Phan, MD, the director of GI Medical Oncology at Houston Methodist, discusses some of the challenges oncologists face with treating patients with pancreatic neuroendocrine tumors (pNETs).


Alexey V. Danilov, MD, PhD

Latest:

Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies

Alexey Danilov, MD, PhD, discusses unmet needs in hematologic malignancies to be discussed at the Bridging the Gaps in Hematologic Malignancies meeting.




Alexis E. Horace, PharmD

Latest:

The Future of Melanoma Treatment

Drugs currently approved by the FDA for treatment of melanoma include aldesleukin, dabrafenib, dacarbazine, ipilimumab, trametinib, and vemurafenib. This article will explore pharmacologic agents currently being investigated for the treatment of melanoma.


Alfred L. Garfall, MD, Abramson Cancer Center

Latest:

Multiple Myeloma: Unmet Needs and Future Directions in Care

After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.


Alfred L. Garfall, MD, MS

Latest:

Dr. Garfall Discusses CAR T-Cell Therapy in Multiple Myeloma

Alfred L. Garfall, MD, MS, discusses the potential of CAR T-cell therapy in multiple myeloma.


Alfredo Addeo, MD

Latest:

Dr. Addeo Discusses the Need for Biomarkers in NSCLC

Alfredo Addeo, MD, consultant medical oncologist, University Hospital of Geneva, discusses the need for effective biomarkers in non–small cell lung cancer.


Ali McBride, PharmD, MS, BCOP

Latest:

Dr. McBride on Biosimilar Rituximab

Ali McBride, PharmD, MS, BCOP, discusses the oncology community’s reaction to biosimilars for rituximab (Rituxan).